In a direct-compression or roller-compacted immediate-release tablet line, aripiprazole API is first delumped through a 500 µm stainless steel screen and then blended at a drug mass fraction that depends on the target label claim of 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, or 30 mg. The free base has low bulk density and moderate cohesive behaviour, so low-dose blends containing less than 1.0% API are particularly susceptible to segregation and content uniformity failure. A production-scale bin blender of 600 L typically requires 15–25 min at 8–12 rpm to reach acceptable blend homogeneity, but published data for this exact formulation configuration is limited. Lactose monohydrate, maize starch, microcrystalline cellulose, hydroxypropyl cellulose, and magnesium stearate are added sequentially; magnesium stearate is screened through a 500 µm mesh and blended for only 3–5 min to avoid excess lubrication and dissolution slowdown. Roller compaction on an Alexanderwerk WP 120 or Gerteis MACRO-PACTOR is operated at a specific roll force of 8–18 kN/cm and a roll gap of 2–4 mm to produce ribbon density of 1.1–1.3 g/cm³; milling through a 0.8–1.0 mm screen gives granules with a D50 in the 180–250 µm range. Tablets are compressed on a 45-station rotary press with flat-faced bevel-edged tooling, precompression force 2–5 kN, and main compression force adjusted to a hardness of 5–10 kP. Friability is maintained below 0.8% after 100 drops when tested according to USP <1216>. Dissolution is evaluated using USP <711> Apparatus 2 at 50 rpm in 900 mL of 0.1 N HCl at 37 °C; in approved immediate-release tablet dossiers, a Q value of 80% at 30 min is commonly applied for aripiprazole tablets. Assay and related substances are determined by reverse-phase HPLC with UV detection at 254 nm, and the finished tablet must satisfy USP <905> uniformity of dosage units with an acceptance value of 15.0 or less. Residual moisture is controlled below 2.0% loss on drying by Ph.Eur. 2.2.32 to prevent polymorphic conversion of the anhydrous form to monohydrate during shelf life. Elemental impurities are assessed according to ICH Q3D, with Class 1 and Class 2A limits applied at the finished-product level on the basis of a 30 mg maximum daily dose.

What Happens to Content Uniformity When a 5 mg Capsule Weighs Less Than 120 mg?

When a 5 mg aripiprazole capsule is filled at a total fill weight below 120 mg, the API mass fraction is 4.2%; for a 2 mg capsule at 100 mg fill weight the fraction drops to 2.0%. Content uniformity risk rises sharply because the API is practically insoluble and is not wet-massed, so the dry blend must be produced by geometric dilution rather than single-pot mixing. A 25 kg high-shear granulator may be used only as a preblender with chopper speed 300–500 rpm and impeller speed 150–250 rpm for 5–8 min; the resulting preblend is then passed through a 600 µm sieve. Lactose monohydrate is the primary diluent, with 0.5% colloidal silicon dioxide added as a glidant and 1.0–2.0% magnesium stearate added as a lubricant. Capsule filling on an MG2 Planeta or Zanasi 6/E continuous motion machine uses size 0 hard gelatin or HPMC shells; speed is typically limited to 50,000–80,000 capsules/h because low fill weight and electrostatic charge reduce powder flow into the dosator nozzle. HPMC shells are preferred for export to ICH Zone IVb markets because gelatin crosslinking under elevated temperature and humidity can reduce dissolution rate and create false failures in USP <711> testing. Process analytical technology such as near-infrared blend uniformity scanning at 15 min intervals with a 10 capsule sample is used to detect segregation before filling. The finished capsules are tested for content uniformity according to USP <905> with an acceptance value of 15.0 or less, and dissolution under USP <711> Apparatus 2 at 50 rpm in 900 mL of 0.1 N HCl with sinkers. Terminal capsule strengths of 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg are produced from the same validated master blend; batch-to-batch variance in fill weight RSD is kept below 2.0% for fill weights above 100 mg.

Granule Layering for Oral Suspension Requires Moisture Control Below 2.5% Loss on Drying

A top-spray fluid-bed granulator with an 18 L bowl and 1.0 mm two-fluid nozzle is used to layer aripiprazole monohydrate onto mannitol and xylitol substrates for sachet-based oral suspension granules. The binder solution is hydroxypropyl cellulose 5.0% w/w in purified water, sprayed at inlet air temperature 60–70 °C and atomization pressure 1.5–2.5 bar; product temperature is maintained below 40 °C during spraying to avoid monohydrate dehydration and agglomeration. Aripiprazole is pre-suspended or pre-dispersed in the binder solution with the aid of 0.1–0.3% polysorbate 80, and the suspension is kept under continuous stirring to prevent sedimentation during spraying. Granule growth is controlled by spray rate ramp from 10 g/min to 25 g/min for a 5 kg batch; after spraying, the material is dried to a loss on drying of 1.5–2.5% by Ph.Eur. 2.2.32. The final granules are screened through a 1.0 mm sieve to remove oversize material; D50 is typically 150–250 µm, and bulk density is 0.55–0.65 g/mL. Crospovidone 3.0% is added as extragranular disintegrant after drying, along with 0.5% colloidal silicon dioxide, sucralose, and orange flavour. Sachet fill weight is 500 mg or 1000 mg depending on the dose; the granules are dispersed in 30–50 mL of water immediately before administration. The suspension pH after reconstitution is controlled between 5.5 and 7.5; viscosity and sedimentation volume are monitored during development because aripiprazole monohydrate undergoes slow wetting in aqueous media. Microbiological quality is assessed by Ph.Eur. 2.6.12 total aerobic microbial count and Ph.Eur. 2.6.13 specified organisms; water activity is maintained below 0.60 to prevent microbial growth in single-dose sachets. The terminal granule dosage form is used in clinical titration kits and in pediatric or dysphagia patient populations where tablet swallowing is compromised.

When Aripiprazole Monohydrate Is Milled to a Dv90 Below 2.5 µm for 28-Day Depot Injection

The long-acting injectable suspension is manufactured from aripiprazole monohydrate that is wet-milled to a Dv90 of 2.5 µm or less and a Dv50 of 1.0–1.5 µm. Milling is performed on a recirculating bead mill with 0.3 mm yttrium-stabilized zirconia beads at a tip speed of 10–14 m/s; the suspension contains mannitol as a tonicity modifier and a cellulosic suspending agent, with pH adjusted to 6.5–7.5 using sodium hydroxide. Particle size is monitored by laser diffraction according to ISO 13320-1:2020 and USP <429>. The milled suspension is filled into vials and lyophilized; the lyophilization cycle must maintain product temperature below -20 °C during primary drying and below 25 °C during secondary drying to avoid dehydration of the monohydrate and irreversible particle aggregation. After reconstitution with sterile water for injection, the suspension concentration is 200 mg/mL; the 300 mg vial is reconstituted with 1.5 mL and the 400 mg vial with 2.0 mL. The dosing volume is given by deep intramuscular gluteal injection; the suspension is designed for 28-day release through slow dissolution of the low-solubility monohydrate particles.

The main process conflict arises because particle size reduction increases both depot dissolution control and Ostwald ripening risk; the cellulosic suspending agent is therefore added to raise low-shear viscosity to 15–40 mPa·s at 25 °C, measured with a Brookfield viscometer at 60 rpm. If the Dv90 exceeds 2.5 µm, injectability through 21 G needles deteriorates and delivered dose uniformity may fail; if the Dv50 falls below 0.5 µm, release may become too fast and the 28-day dosing interval cannot be maintained. Lyophilization also requires precise control of the frozen-state microstructure, because collapse or meltback leads to cakes that are difficult to reconstitute and may trap API agglomerates. The sterile diluent is filled in separate vials and must meet USP <71>, USP <85>, and USP <788> requirements as a water for injection-based product.

Because aripiprazole free base remains practically insoluble at neutral pH, a short-acting intramuscular injection is formulated in an acidified aqueous vehicle rather than as a neutral suspension. The API is dissolved at a concentration of 7.5 mg/mL in a vehicle containing an organic acid buffer and water for injection; the solution pH is maintained between 2.8 and 3.5 to keep the protonated tertiary amine in solution. The solution is sterile-filtered through a 0.22 µm PVDF membrane into sterilized 2 mL Type I glass vials; fill volume is 1.3 mL with a small overage to compensate for needle hub loss during withdrawal. Terminal analysis includes assay by HPLC with UV detection at 254 nm, pH by USP <791>, osmolality by USP <785>, particulate matter by USP <788>, sterility by USP <71>, and bacterial endotoxin by USP <85>. Vial compatibility is evaluated under USP <660> for glass surface durability and USP <1663> extractables assessment; terminal sterilization of the acidified solution is usually limited to aseptic filtration because terminal heat sterilization can cause pH shift and degradation of aripiprazole-related impurities. The marketed single-dose vial delivers 9.75 mg of aripiprazole per 1.3 mL injection. Intramuscular administration is normally into the deep deltoid or gluteal muscle using a 21–23 G needle; the injection is not intended for intravenous use, and any visible precipitate formed by neutralization with blood can be avoided by ensuring appropriate needle length and injection depth. The short-acting injection is used for acute agitation in schizophrenia or bipolar mania; the terminal product is stable in the acidified solution as long as pH is held below the upper control limit, because solubility drops sharply when pH approaches the pKa of aripiprazole.

Orally Disintegrating Tablets, Lyophilized Oral Lyophilisate Platforms, and Polymorph Conversion Risk

The manufacture of orally disintegrating tablets introduces a direct conflict between mechanical strength and disintegration speed, and this conflict is more severe for aripiprazole because the API is hydrophobic and can become trapped in polymer matrices. Two routes are used: freeze-drying of a suspension in preformed blister pockets, and direct compression of mannitol-based granules with high levels of crospovidone. In the freeze-drying route, aripiprazole monohydrate is dispersed in a solution of gelatin or fish gelatin, mannitol, and xanthan gum, then dosed into 0.5 mL blister pockets and lyophilized. The finished unit disintegrates in less than 30 s when tested by USP <701> in 900 mL water at 37 °C, but mechanical strength is limited to handling without direct push-through force. In the direct compression route, mannitol with a D50 of 100–150 µm, crospovidone 5–10%, microcrystalline cellulose 10–20%, sucralose, and an orange or peppermint flavour are blended with API; compression force is kept below 8 kN to avoid densification that slows water ingress. The resulting tablet hardness is 20–40 N, friability is below 1.0%, and disintegration time is 15–60 s by USP <701>. Freeze-dried blister packaging uses PVC/PCTFE/aluminium laminates with moisture vapour transmission rate below 0.05 g/m²/day to prevent moisture ingress and polymorph conversion. Polymorph conversion risk is controlled by maintaining process RH below 60% and product moisture below 2.0%; if the anhydrous form is used, contact with aqueous binder solutions can cause conversion to monohydrate, which changes dissolution behaviour and requires revalidation. Terminal strengths are 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg.